Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study

por Hayashi, Norio, Seto, Chiharu, Kato, Mai, Komada, Yuji, Goto, Shoichiro
Publicado 2013

Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin

por Nakayama, Masahiko, Kobayashi, Hisanori, Fukushima, Koji, Ishido, Miwako, Komada, Yuji, Yoshizawa, Kazutake
Publicado 2015